JALEESA HARRIS: Open Payments
NPI 1093472219 · MOBILE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$768 in 32 payments from 13 companies in 2025. Trend: 2023 $1,812 · 2024 $1,862 · 2025 $768
Food & beverage: $768
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 11 | $316 |
| ACADIA Pharmaceuticals Inc | 3 | $73 |
| Neurelis, Inc. | 3 | $69 |
| SK Life Science, Inc. | 2 | $67 |
| UPSHER-SMITH LABORATORIES LLC | 3 | $62 |
| Genentech USA, Inc. | 2 | $37 |
| ARGENX US, INC. | 1 | $29 |
| JAZZ PHARMACEUTICALS INC. | 1 | $23 |
| Aucta Pharmaceuticals, Inc. | 2 | $22 |
| EMD Serono, Inc. | 1 | $20 |
Products named: Fintepla, VALTOCO, NUPLAZID, VIGAFYDE, Briviact, VYVGART HYTRULO, DAYBUE, EPIDIOLEX.
Industry payments across AL — which companies pay providers there.
